Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma

International Journal of Laboratory Hematology

Volumn 34, Issue 5, 2012, Pages 541-546

  Shin, S Y ^a   Jang, S ^a   Park, C J ^a   Chi, H S ^a   Lee, J H ^a   Lee, K H ^a   Suh, C ^a   Lim, S E ^b   Seo, Eul Ju ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

FISH; Immune magnetic sorting; Multiple myeloma; Plasma cell purification

Indexed keywords

INTERLEUKIN 4; MAGNETIC NANOPARTICLE; SYNDECAN 1;

ARTICLE; BONE MARROW CELL; CELL SELECTION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNE MAGNETIC CELL SORTING; IMMUNOPHENOTYPING; KARYOTYPING; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PURIFICATION;

CELL COUNT; CELL CULTURE TECHNIQUES; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; PLASMA CELLS; REPRODUCIBILITY OF RESULTS; SYNDECAN-1;

EID: 84865564492     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01433.x     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007;20:625-35.
3. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529-34.
4. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Harousseau JL, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
5. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985;66:380-90.
6. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-9.
7. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-38.
8. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jager U, Heinz R. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995;55:3854-9.
9. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358-60.
10. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.
11. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-75.
12. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:125-30.
13. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-5.
14. Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000;18:804-12.
15. Wang D, Huang L, Zhang H, Geng Z, Shang Z, Zhou JF, Li CR. Application of FICTION technique to the detection of genetic aberrations in multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2011;32:226-30.
16. Slovak ML, Bedell V, Pagel K, Chang KL, Smith D, Somlo G. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization. Cancer Genet Cytogenet 2005;158:99-109.
17. Margaret J, Barch TK, Spurbeck TL. The AGT Cytogenetics Laboratory Manual. 3rd edn, Philadelphia: Lippincott-Raven Publishers; 2009.
18. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
19. Put N, Lemmens H, Wlodarska I, Konings P, Moreau Y, Hagemeijer A, Vandenberghe P, Michaux L. Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosom Cancer 2010;49:991-7.
20. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489-95.
21. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-91.
22. Swerdelow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn, Lyon, France: IARC Press; 2008.